Virtual seminar | Watch on demand (25 mins)

Around 40% of global drug licensing deals now involve Chinese assets, up from under 5% in 2020. Yet many of those assets take 12 to 18 months to show up on Western radars.
In this virtual seminar, building on our Pharma CI USA 2026 session, Ryan Caradonna and Jatin Gupta explore why standard global CI approaches fall short in China, and what it takes to close the gap.
What you’ll learn:
- Why BD&L, clinical development, manufacturing and supply chain, and local commercial effectiveness are all incomplete without a China view
- Why up to 35% of global assets sit behind China’s firewall
- The six barriers that make China hard to see, from hidden trial activity to an inverted KOL hierarchy
- How provincial-level primary CI changed a top 20 pharma company’s forecast and strategy
- What a China trial record reveals that ClinicalTrials.gov doesn’t